Vigonvita Life Sciences Co., Ltd. (Stock Code: 2630) has entered into a license agreement with Simcere Pharmaceutical Group Limited, granting Simcere Pharmaceutical exclusive rights in Greater China to develop and commercialize VV116 (Deuremidevir Hydrobromide) for the treatment of respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections. The collaboration aims to leverage both parties’ research and development, production, and commercialization capabilities to accelerate clinical development and expand patient access.

VV116 is a novel oral nucleoside prodrug, which received conditional marketing approval in January 2023 for the treatment of mild to moderate COVID-19 infections and was converted to regular approval in January 2025. Studies have shown VV116’s broad-spectrum antiviral activity, including a Phase II clinical trial for RSV in infants and young children that demonstrated positive results, supported by the Breakthrough Therapy Designation from the Center for Drug Evaluation of the National Medical Products Administration. Preclinical research indicates VV116’s substantial antiviral potential, while clinical trials have shown favorable overall safety with no serious adverse events reported.

Simcere Pharmaceutical, listed on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 2096.HK), focuses on innovative research in neuroscience, anti-oncology, autoimmune, and anti-infection treatments. Vigonvita, established in 2013, is an innovation-driven biopharmaceutical company focused on novel drug development in neuropsychiatry, reproductive health, and viral infection, with an integrated system spanning lead discovery, preclinical and clinical research, manufacturing, and commercialization. The announcement is dated December 3, 2025.